Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2008 2
2009 1
2010 1
2011 2
2012 4
2013 5
2014 3
2015 2
2016 1
2017 1
2018 1
2019 2
2020 4
2021 4
2022 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean daniel avena (19 results)?
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.
Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, Agarwal N, Parikh RA, Vaena DA, Ryan CW, Hashmi M, Costello BA, Cella D, Dutcher JP, DiPaola RS, Haas NB, Wagner LI, Carducci MA. Appleman LJ, et al. Among authors: vaena da. J Clin Oncol. 2024 Mar 26:JCO2301544. doi: 10.1200/JCO.23.01544. Online ahead of print. J Clin Oncol. 2024. PMID: 38531002
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
Stricker T, Jain N, Ma E, Yu E, Wang R, Schuldt R, Price R, Szado T, Sussell J, Ogale S, Lin V, Arrowsmith E, Slater D, Vaena D, Staszewski H, Fang B, Seneviratne L, Daniel D. Stricker T, et al. Among authors: vaena d. Oncologist. 2024 Feb 28:oyae022. doi: 10.1093/oncolo/oyae022. Online ahead of print. Oncologist. 2024. PMID: 38417095 Free article.
Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
Schwartzberg L, Daniel D, Vaena D, Slater D, Staszewski H, Fang B, Seneviratne L, Yu E, Price R, Szado T, Meyer CS, Shah A, Ma E. Schwartzberg L, et al. Among authors: vaena d. Future Oncol. 2023 Jun;19(20):1397-1414. doi: 10.2217/fon-2022-1216. Epub 2023 Jun 15. Future Oncol. 2023. PMID: 37318757 Free article.
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
Agarwal N, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM Jr, Quinn DI. Agarwal N, et al. Among authors: vaena da. J Clin Oncol. 2022 Oct 1;40(28):3301-3309. doi: 10.1200/JCO.21.02517. Epub 2022 Apr 21. J Clin Oncol. 2022. PMID: 35446628 Free PMC article. Clinical Trial.
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
Rosenberg JE, Ballman KA, Halabi S, Atherton PJ, Mortazavi A, Sweeney C, Stadler WM, Teply BA, Picus J, Tagawa ST, Katragadda S, Vaena D, Misleh J, Hoimes C, Plimack ER, Flaig TW, Dreicer R, Bajorin D, Hahn O, Small EJ, Morris MJ. Rosenberg JE, et al. Among authors: vaena d. J Clin Oncol. 2021 Aug 1;39(22):2486-2496. doi: 10.1200/JCO.21.00286. Epub 2021 May 14. J Clin Oncol. 2021. PMID: 33989025 Free PMC article. Clinical Trial.
Comprehensive review of chromophobe renal cell carcinoma.
Garje R, Elhag D, Yasin HA, Acharya L, Vaena D, Dahmoush L. Garje R, et al. Among authors: vaena d. Crit Rev Oncol Hematol. 2021 Apr;160:103287. doi: 10.1016/j.critrevonc.2021.103287. Epub 2021 Mar 19. Crit Rev Oncol Hematol. 2021. PMID: 33753250 Free article. Review.
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).
Goldkorn A, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN Jr, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM Jr, Agarwal N. Goldkorn A, et al. Among authors: vaena da. Clin Cancer Res. 2021 Apr 1;27(7):1967-1973. doi: 10.1158/1078-0432.CCR-20-3587. Epub 2021 Jan 26. Clin Cancer Res. 2021. PMID: 33500355 Free PMC article. Clinical Trial.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Hussain M, et al. N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20. N Engl J Med. 2020. PMID: 32955174 Free article. Clinical Trial.
34 results